ArticleHepatobiliary surgery and nutrition2023

CRISPR-edited hepatic organoids as drug screening platform for non-alcoholic fatty liver disease.

Yinhan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.